Immune checkpoint inhibitors have revolutionized cancer therapy, but their success is limited by a lack of preexisting anticancer T cells or the inability of anticancer T cells to overcome the immunosuppressive tumor microenvironment.
Various approaches to overcoming these challenges have been investigated, but the complexity of the immune system suggests that intervention at multiple points is required to effectively activate antitumor immunity.
Lerapolturev has been administered to more than 200 patients and is currently the subject of multiple ongoing phase 2 trials across multiple solid tumors.
Breakthrough Therapy
Orphan Drug Designation
Fast Track
Orphan Drug Designation
Lerapolturev has been designated an Orphan Drug and granted Breakthrough Therapy Designation for recurrent glioblastoma (rGBM) by the FDA.
Lerapolturev has also been designated an Orphan Drug in advanced melanoma (Stages IIb-IV) and granted Fast Track status for patients with advanced melanoma who have disease progression after anti–PD-1/L1 therapy.
